Phase III study of afatinib or cisplatin plus pemetrexed in patients with metastatic lung adenocarcinoma with EGFR mutations.

By L. Sequist, Jie Yang, N. Yamamoto, K. O'Byrne, V. Hirsh, T. Mok, Sarayut Lucien Geater, S. Orlov, C. Tsai, M. Boyer and 10 more. Journal of Clinical Oncology, 2013

3,142 citations recorded by the source corpus.

Subfields: Oncology, Pulmonary and Respiratory Medicine

View Paper: https://www.semanticscholar.org/paper/fd01dcf80060ce9c4dada7f82d9af0017d1848ac

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Oncology

1. Jin-Yuan Shih
2. Shang-Gin Wu
3. William Pao

In Pulmonary and Respiratory Medicine

1. Jin-Yuan Shih
2. B. Hughes
3. Shang-Gin Wu
4. B. Chan
5. William Pao

Citations in the corpus

• Management of acquired resistance to EGFR TKI–targeted therapy in advanced non-small cell lung cancer (2018, positive): “Although EGFR-mutant patients receiving EGFR TKIs have longer median PFS than those receiving platinumbased chemotherapy as first-line treatment [5, 6, 19, 20], acquired resistance to EGFR TKIs eventually emerges.”
• Kinase-targeted cancer therapies: progress, challenges and future directions (2018, background): “Afatinib, a second-generation, non-competitive kinase inhibitor targeting all members of the ErbB family of receptors (also known as Her-2/neu) was approved in 2013 as frontline therapy for NSCLC patients with EGFR-deletion 19 and L858R mutations [170].”